{"id":1333,"date":"2016-10-01T02:56:44","date_gmt":"2016-09-30T23:56:44","guid":{"rendered":"http:\/\/www.akturk.com\/en\/?p=1333"},"modified":"2016-10-01T02:56:44","modified_gmt":"2016-09-30T23:56:44","slug":"bayer-to-acquire-monsanto-for-66-billion","status":"publish","type":"post","link":"https:\/\/www.akturk.com\/en\/2016\/10\/01\/bayer-to-acquire-monsanto-for-66-billion\/","title":{"rendered":"Bayer to acquire Monsanto for $ 66 billion"},"content":{"rendered":"<p>The improved takeover offer of $66 billion, including debt, is the largest cash bid on record<\/p>\n<p>German drugs and crop chemicals company Bayer has won over U.S. seeds firm Monsanto with an improved takeover offer of $66 billion including debt, ending months of wrangling after increasing its bid for a third time.<\/p>\n<p>The $128 a share deal announced on Wednesday, up from Bayer&#8217;s previous offer of $127.50 a share, is the biggest of the year so far and the largest cash bid on record. The transaction will create a company commanding more than a quarter of the combined world market for seeds and pesticides in a fast-consolidating farm supplies industry.<\/p>\n<p>However, competition authorities are likely to scrutinise the tie-up closely, and some of Bayer&#8217;s own shareholders have been critical of a takeover plan which they say is too expensive and risks neglecting the company&#8217;s pharmaceutical business.<\/p>\n<p>\u201cBayer&#8217;s competitors are merging, so not doing this deal would mean having a competitive disadvantage,\u201d said Markus Manns, a fund manager at Union Investment, one of Bayer&#8217;s top 12 investors, according to ThomsonReuters data.<\/p>\n<p>He said few people had expected a deal to be agreed at less than $130 a share, but that there were regulatory risks and the acquisition would also leave Bayer with less scope to invest in healthcare, where rivals are consolidating too.<\/p>\n<p>Break-fee<\/p>\n<p>The transaction includes a break-fee of $2 billion that Bayer will pay to Monsanto should it fail to get regulatory clearance. Bayer expects the deal to close by the end of 2017.<\/p>\n<p>The details confirm what a source close to the matter told Reuters earlier.<\/p>\n<p>Baader Helevea Equity Research analyst Jacob Thrane, who has a \u201csell\u201d rating on Bayer shares, said the German company was paying 16.1 times Monsanto&#8217;s forecast core earnings for 2017, more than the 15.5 times ChemChina agreed to pay for Swiss crop chemicals firm Syngenta last year.<\/p>\n<p>He also said there was uncertainty over what the combined company would look like as regulators might demand asset sales.<\/p>\n<p>Some analysts said the deal could face a rough ride from U.S. politicians opposed to a key supplier of U.S. agriculture falling into foreign hands and from farmers concerned a reduction in competition could lead to higher prices.<\/p>\n<p>Bayer said it needed approval from antitrust authorities in 30 jurisdictions, but its initial feedback from both regulators and politicians was encouraging.<\/p>\n<p>The German firm said it expected the deal to boost core earnings per share in the first full year following completion, and by a double-digit percentage in the third year. It is targeting $1.2 billion in annual cost synergies and $300 million in sales synergies after three years.<\/p>\n<p>Bayer&#8217;s move to combine its crop chemicals business, the world&#8217;s second largest after Syngenta, with Monsanto&#8217;s industry leading seeds business, is the latest in a series of major tie-ups in the agrochemicals sector.<\/p>\n<p>The German company is aiming to create a one-stop shop for seeds, crop chemicals and computer-aided services to farmers.<\/p>\n<p>That was also the idea behind Monsanto&#8217;s swoop on Syngenta last year, which the Swiss company fended off, only to agree later to a takeover by China&#8217;s state-owned ChemChina.<\/p>\n<p>Elsewhere, U.S. chemicals giants Dow Chemical and DuPont plan to merge and later spin off their respective seeds and crop chemicals operations into a major agribusiness.<\/p>\n<p>\u201cThe combined business will be ideally suited to cater to the requirements of farmers &#8230; because we have equal and meaningful strength in both crop protection, seeds and traits, and digital and analytical tools,\u201d Bayer Chief Executive Werner Baumann said on a call with analysts.<\/p>\n<p>The deal will be the largest ever involving a German buyer, beating Daimler&#8217;s tie-up with Chrysler in 1998, which valued the U.S. carmaker at more than $40 billion. It will also be the largest all-cash transaction on record, ahead of brewer InBev&#8217;s $60.4 billion offer for Anheuser-Busch in 2008.<\/p>\n<p>44 per cent premium<\/p>\n<p>Bayer said it was offering a 44 per cent premium to Monsanto&#8217;s share price on May 9, the day before it made its first written proposal.<\/p>\n<p>It plans to raise $19 billion to help fund the deal by issuing convertible bonds and new shares to its existing shareholders.<\/p>\n<p>Here are some key points in the deal:<\/p>\n<p>Bayer agrees $128 per share cash bid to buy Monsanto<br \/>\nDeal includes a $2 billion break-up fee<br \/>\nBayer says expects deal to close by end-2017 (Repeats to fix formatting. No change to text) <\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content -->","protected":false},"excerpt":{"rendered":"<p>The improved takeover offer of $66 billion, including debt, is the largest cash bid on record German drugs and crop chemicals company Bayer has won over U.S. seeds firm Monsanto with an improved takeover offer of $66 billion including debt, ending months of wrangling after increasing its bid for a third time. The $128 a [&hellip;]<!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39],"tags":[],"class_list":["post-1333","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.akturk.com\/en\/wp-json\/wp\/v2\/posts\/1333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.akturk.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.akturk.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.akturk.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.akturk.com\/en\/wp-json\/wp\/v2\/comments?post=1333"}],"version-history":[{"count":1,"href":"https:\/\/www.akturk.com\/en\/wp-json\/wp\/v2\/posts\/1333\/revisions"}],"predecessor-version":[{"id":1334,"href":"https:\/\/www.akturk.com\/en\/wp-json\/wp\/v2\/posts\/1333\/revisions\/1334"}],"wp:attachment":[{"href":"https:\/\/www.akturk.com\/en\/wp-json\/wp\/v2\/media?parent=1333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.akturk.com\/en\/wp-json\/wp\/v2\/categories?post=1333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.akturk.com\/en\/wp-json\/wp\/v2\/tags?post=1333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}